Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours

Digestive and Liver Disease

Volumn 42, Issue 9, 2010, Pages 635-641

  Massironi, Sara ^a   Conte, Dario ^a,b   Sciola, Valentina ^a,b   Pirola, Lorena ^a,b   Paggi, Silvia ^a   Fraquelli, Mirella ^a   Ciafardini, Clorinda ^a   Spampatti, Matilde P ^a   Peracchi, Maddalena ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Carcinoids; Contrast enhanced ultrasonography; Gastroenteropancreatic neuroendocrine tumours; Liver metastases; Pancreatic endocrine tumours

Indexed keywords

IOMEPROL; KI 67 ANTIGEN; SONOVUE;

ADULT; AGED; ARTICLE; CARCINOID; CONTRAST ENHANCEMENT; DUODENUM CANCER; ECHOGRAPHY; FEMALE; GASTRINOMA; HUMAN; ILEUM CANCER; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PRIORITY JOURNAL; RECTUM CANCER; STOMACH CANCER;

EID: 77955282308     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.01.009     Document Type: Article

References (38)

1. Yao J.C., Hassan M., Phan A., et al. One hundred years after " carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
2. Modlin I.M., Oberg K., Chung D.C., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9:61-72.
3. Delaunoit T., Neczyporenko F., Rubin J., et al. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol 2008, 103:475-483.
4. Massironi S., Sciola V., Peracchi M., et al. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008, 14:5377-5384.
5. Metz D.C., Jensen R.T. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008, 135:1469-1492.
6. Rindi G., D'Adda T., Froio E., et al. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007, 18:145-149.
7. Steinmüller T., Kianmanesh R., Falconi M., et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008, 87:47-62.
8. Rockall A.G., Reznek R.H. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007, 21:43-68.
9. Falconi M., Plockinger U., Kwekkeboom D.J., et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006, 84:196-211.
10. Reznek R.H. CT/MRI of neuroendocrine tumours. Cancer Imaging 2006, 6:S163-S177.
11. Bartolozzi C., Cioni D., Donati F., et al. Focal liver lesions: MR imaging-pathologic correlation. Eur Radiol 2001, 11:1374-1388.
12. Baron R.L., Oliver J.H., Dodd G.D., et al. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996, 199:505-511.
13. von Herbay A., Westendorff J., Gregor M. Contrast-enhanced ultrasound with SonoVue®: differentiation between benign and malignant focal liver lesions in 317 patients. J Clin Ultrasound 2010, 38:1-9.
14. Quaia E., Calliada F., Bertolotto M., et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004, 232:420-430.
15. Morin S.H., Lim A.K., Cobbold J.F., et al. Use of second generation contrast-enhanced ultrasound in the assessment of focal liver lesions. World J Gastroenterol 2007, 13:5963-5970.
16. Fulcher A.S., Sterling R.K. Hepatic neoplasms: computed tomography and magnetic resonance features. J Clin Gastroenterol 2002, 34:463-471.
17. Stafford-Johnson D.B., Francis I.R., Eckhauser F.E., et al. Dual-phase helical CT of nonfunctioning islet cell tumors. Comput Assist Tomogr 1998, 22:335-339.
18. Van Hoe L., Gryspeerdt S., Marchal G., et al. Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. Am J Roentgenol 1995, 165:1437-1439.
19. Chung M.J., Choi B.I., Han J.K., et al. Functioning islet cell tumor of the pancreas. Localization with dynamic spiral CT. Acta Radiol 1997, 38:135-138.
20. Mörk H., Ignee A., Schuessler G., et al. Analysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography. Scand J Gastroenterol 2007, 42:652-662.
21. Malagò R., D'Onofrio M., Zamboni G.A., et al. Contrast-enhanced sonography of nonfunctioning pancreatic neuroendocrine tumors. Am J Roentgenol 2009, 192:424-430.
22. Dörffel Y., Wermke W. Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography. Ultraschall Med 2008, 29:506-514.
23. Rickes S., Ocran K.W., Gerstenhauer G., et al. Evaluation of diagnostic criteria for liver metastases of adenocarcinomas and neuroendocrine tumours at conventional ultrasound, unenhanced power Doppler sonography and echo-enhanced ultrasound. Dig Dis 2004, 22:81-86.
24. D'Onofrio M., Rozzanigo U., Masinielli B.M., et al. Hypoechoic focal liver lesions: characterization with contrast enhanced ultrasonography. J Clin Ultrasound 2005, 33:164-172.
25. Hoeffel C., Job L., Ladam-Marcus V., et al. Detection of hepatic metastases from carcinoid tumor: prospective evaluation of contrast-enhanced ultrasonography. Dig Dis Sci 2009, 54:2040-2046.
26. Solcia E.K.G., Klöppel G., Sobin L.H. Histological typing of endocrine tumors. WHO international histological classification of tumors 2000, Springer, Berlin, p. 56-70. 2nd ed.
27. Rindi G., Klöppel G., Alhman H., et al. European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449:395-401.
28. Rindi G., Klöppel G., Couvelard A., et al. TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007, 451:757-762.
29. Piscaglia F., Corradi F., Mancini M., et al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer 2007, 7:171.
30. Claudon M., Cosgrove D., Albrecht T., et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS)-update 2008. Ultraschall Med 2008, 29:28-44.
31. Lencioni R., Della Pina C., Crocetti L., et al. Clinical management of focal liver lesions: the key role of real-time contrast-enhanced US. Eur Radiol 2007, 17(Suppl. 6):F73-F79.
32. Giorgio A., Ferraioli G., Tarantino L., et al. Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. Am J Roentgenol 2004, 183:1319-1326.
33. Schütte K., Bornschein J., Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009, 27:80-92.
34. Mehta S.R., Thomas E.L., Bell J.D., et al. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008, 14:3476-3483.
35. Jamali M., Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 2008, 19:282-288.
36. Arnold R., Wilke A., Rinke A., et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008, 6:820-827.
37. Albrecht T., Blomley M., Bolondi L., et al. Guidelines for the use of contrast agents in ultrasound. Ultraschall Med 2004, 25:249-256.
38. Steinmuller T., Kianmanesh R., Falconi M., et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008, 87:47-62.